CD8A and melanoma: Repeated oral administration of the nanoplatform increased the populations of CD3+ CD8+ T cells, CD44high CD62Llow memory T cells, and CD11b+ CD27+ natural killer cells in the blood, while reducing serum levels of CD4+ CD25+ Foxp3+ regulatory T cells, thereby completely preventing melanoma development in melanoma-bearing mice [96].